AUROBINDO PHARMA
|
The Current P/E Ratio of AUROBINDO PHARMA is 17.90.
Share Price | ₹1,083.3 | Jun 19,2025 |
Market Cap | ₹62,915.2 Cr | |
Earnings-TTM | ₹3,515.3 Cr | TTM-Consolidated Results |
Price/Earnings | 17.90x | Calculated as Market Cap/Earnings |
---|---|---|
Explore Stock Analytics |
Definition & Calculation of PE (Price/Earnings) ratio of AUROBINDO PHARMA
P/E =
Market Capitalization
/ Net Income
or, using per-share numbers:
P/E = Stock Price /
Earnings Per Share (EPS)
Current Market Cap [ ₹62,915.2 Cr] as on Jun 19,2025
(/) Earnings [ ₹3,515.3 Cr] based on TTM-Consolidated Results
(=) P/E Ratio [ 17.90x ]
Thus, for AUROBINDO PHARMA , the investors are currently willing to pay 17.90 times earnings to own 1 share of the company.
PE Multiples are the most widely used valuation multiple in practice.
Since P/E ratio uses Net Income in the calculation, P/E multiples are not always reliable for valuing companies with negative earnings.
In such cases, you may consider using Price to Book ratio or Price to Sales ratio of AUROBINDO PHARMA !
P/E ratios, also, would not adjust for differences in the capital structure between companies.
The chart below summarizes the trend in P/E Ratio of AUROBINDO PHARMA over the last five years.
Historical PE (Price/Earnings) ratio chart of AUROBINDO PHARMA
PE Ratio Performance Analysis for AUROBINDO PHARMA
- AUROBINDO PHARMA 's p/e ratio for fiscal years ending Mar2024 to Mar2020 averaged 13.77x.
- AUROBINDO PHARMA 's operated at median p/e ratio of 14.8x from fiscal years ending March 2018 to 2022.
- Looking back at the last 5 fiscal years, AUROBINDO PHARMA 's p/e ratio peaked in Mar2024 at 20.12x.
- AUROBINDO PHARMA 's p/e ratio hit its five-year low in Mar2020 of 8.51x.
How does AUROBINDO PHARMA 's P/E Ratio benchmark against top 10 peers in Pharmaceuticals & Drugs Industry?
Peer Comparison (Pharmaceuticals & Drugs Industry) | Earnings-TTM (Cr) | PE Ratio | Market Cap |
---|---|---|---|
AUROBINDO PHARMA | 3,515.26 | 17.90 | 62,915.2 |
SUN PHARMACEUTICAL INDUSTRIES LTD | 10,980.10 | 36.00 | 395,254.0 |
DIVIS LABORATORIES LTD | 2,191.00 | 78.67 | 172,374.0 |
CIPLA LTD | 5,291.05 | 22.64 | 119,795.0 |
TORRENT PHARMACEUTICALS LTD | 1,911.00 | 56.11 | 107,218.0 |
DR REDDYS LABORATORIES LTD | 5,703.50 | 19.41 | 110,698.0 |
MANKIND PHARMA LTD | 2,003.22 | 47.86 | 95,866.6 |
ZYDUS LIFESCIENCES LTD | 4,614.80 | 20.71 | 95,577.1 |
LUPIN LTD | 3,306.26 | 26.69 | 88,256.4 |
ABBOTT INDIA LTD | 1,414.44 | 46.59 | 65,898.5 |
ALKEM LABORATORIES LTD | 2,216.00 | 25.78 | 57,123.4 |
Pharmaceuticals & Drugs Industry Benchmark (Top 10) PE Analysis vs AUROBINDO PHARMA 's P/E Ratio
Top 10 Industry Peers | PE Ratio |
---|---|
Min industry PE | 17.90x |
Max industry PE | 78.67x |
Median industry PE | 26.69x |
Average industry PE | 36.21x |
You may also like the below Video Courses